INTRODUCTION

Evidence-based medicine (EBM) was introduced to the medical literature in a 1992
article by the Evidence-based Working Group at McMaster University Health Sciences Centre in Canada to describe the clinical learning strategy they had been developing for over a decade. [1] The principles of EBM are being applied to the veterinary profession under the term evidencebased veterinary medicine (EBVM). [2] [3] [4] The underlying concepts of EBM and EBVM are rooted in clinical epidemiology and are not new, but are a formal and explicit effort to increase the occurrence of basing clinical decisions on a dispassionate review of published trials that adequately meet a priori standards of experimental design and experimental execution.
Although most clinical decisions in veterinary medicine are based on evidence of some type, some evidence is very strong (rigorously tested in the target species under natural conditions (e.g. cattle in commercial feedlots) in experiments designed to prove a theory to be false), some evidence is very weak (not tested), and some is intermediate. [5] [6] [7] The hierarchy of evidence is based on the strength of evidence for causation, the ability of the study to control bias, and the similarity between the study population and the population currently being considered in a clinical setting.
With respect to bacterial vaccination in feedlot cattle, sources regarded as the strongest evidence for the effectiveness of vaccination against Mannheimia haemolytica, Pasteurella multocida and Histophilus somni for mitigating the incidence and effect of bovine respiratory disease (BRD) complex are randomized controlled clinical trials in feedlot cattle under a typical husbandry environment with adequate blinding of investigators, a clear case-definition of BRD, and adequate intensity and length of follow-up; or systematic reviews of more than one trial that meet these criteria. In addition, other available evidence, including: studies testing the effects of vaccination of cattle exposed to pathogen-challenged disease models, studies testing the effects of vaccination of cattle in dissimilar production settings (i.e. dairy calves), and studies utilizing in vitro methodologies to test vaccination effects can be used as indirect indicators in the clinical decision-making process, particularly when higher levels of evidence are lacking.
The 'body-of-evidence' for this clinical question is the sum of multiple studies investigating the effect of vaccines against Mannheimia haemolytica, Pasteurella multocida and Histophilus somni administered to cattle. Each individual research study contributes to that body of evidence and each publication can be ranked on a scale from weak evidence to very strong evidence; which for the veterinary practitioner, implies an increasing confidence in recommendations based on a particular study. And, although a simple ranking of experimental trial types is helpful to describe ascending levels of evidence, by its simplistic nature, it incorrectly depicts levels of evidence as a one dimensional and straightforward hierarchy. For example, veterinarians are often confronted with determinations such as, which is better evidence, a randomized trial in three month-old dairy calves (i.e. non-target animals, but a study design with high control of bias and confounding), or a pathogen-challenged disease model study in feedlot cattle (i.e. study with less external validity but in the target population)? In these situations, the clinical expertise, experience, and judgment of the veterinarian must be utilized to aid the ranking of evidence generated by these studies and to guide recommendations for use of bacterial respiratory pathogen vaccines into processing protocols in the field.
Veterinarians considering the strength of evidence must use several perspectives to determine the reliability of research for clinical use.
1) The first consideration is the internal validity of the research, which is determined by the study method and appropriate use of controls for bias. Research reports with good internal validity provide assurance that the results represent an unbiased estimate of the true direction and magnitude of the treatment effect in the study population. For randomized controlled studies, accepted methods of random allocation and blinding of study investigators to the treatment for each experimental unit are key experimental design features to avoid bias and confounding.
2) The second consideration is the population used in the research and its appropriateness as a model for the population that generated the clinical question. Generally, the target species in similar housing and husbandry environments provides stronger evidence than the target species in significantly different housing and husbandry environments, related species, unrelated species, or in-vitro methods.
3) And thirdly the clinical relevance of the outcomes of the research should be considered with patient-or herd-oriented outcomes (such as morbidity risk, mortality risk, or average daily weight gain) providing more direct evidence of intervention effectiveness than disease-oriented outcome measurements such as behavior frequency, body temperature, or antibody response.
Using these considerations, the highest rating in all three dimensions would provide the highest level of evidence.
MATERIALS AND METHODS
A literature search was conducted to identify studies published in English that reported abstracts (379) and Biologic Abstracts (160) followed by a hand search through cited references (4) . A published manuscript is considered a "study" while a "trial" is a direct comparison of a vaccine treatment to a control treatment within a study. A single study may include more than one trial. After reading the abstract from each unique publication, thirty-four studies were included in this review. Fifteen studies (twenty-two trials) were considered the highest level of evidence in that they were trials utilizing feedlot or stocker cattle in North American production settings appropriately allocated to treatment groups with naturally occurring disease. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] One or more trials from five other studies were identified that utilized feedlot cattle in typical North American production settings, but they were weakened by lack of blinding, treatment being confounded by arrival group or other vaccine treatment, or significant loss-to-follow up and were discarded from the summary. [23] [24] [25] [26] [27] In addition, three terminal studies (five trials) investigated the use of commercially available vaccines in feedlot cattle with a pathogen-challenged disease model [14, 28, 29] , three studies (five trials) utilized dairy or beef calves with naturally occurring disease to investigate effects of vaccination [27, 30, 31] , and thirteen studies investigated the use of commercially available vaccines in dairy calves with an induced-disease model. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Studies were excluded from the review: if they did not report original data (primary study), if they did not include a non-vaccinated/placebo control group, if the outcome did not include an assessment of morbidity risk, mortality risk, or extent of lung involvement (e.g. only reported serologic titers), or if the same results were published in a more complete form elsewhere. Many studies did not report specific allocation schemes used or whether or not effective blinding occurred, and some studies utilized inappropriate statistical tests for the data collected. Studies with obvious limitations due to experimental design were excluded, but studies with poorly described experimental designs were retained.
A meta-analysis was done and a Mantel-Haenszel risk ratio (RR) and 95% confidence interval (95% CI) were calculated for each trial reporting cumulative incidence of BRD morbidity or mortality (or crude morbidity or mortality). [45] Calculated RR less than 1.0 indicates that vaccinates had lower cumulative incidence compared to controls; while RR greater than 1.0 indicates that vaccinates had higher cumulative incidence compared to controls. In order to be considered to have a statistically significantly lower morbidity or mortality cumulative incidence in vaccinates compared to controls, the upper limit of the 95% confidence interval must be below 1.0; while in order to consider the cumulative incidence of morbidity or mortality to be statistically significantly higher in vaccinates compared to controls, the lower limit of the 95% confidence interval must be greater than 1.0. A Forest plot is provided to demonstrate graphically the relative strength of the treatment effects.
RESULTS
Studies utilizing feedlot cattle with naturally occurring disease (Appendix 1)
Data was extracted from the fifteen studies (twenty-two trials) that tested the effectiveness of vaccination against one or more of the bacterial pathogens: Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in feedlot cattle for mitigating the incidence and effect of bovine respiratory disease complex using feedlot cattle with naturally occurring disease in order to calculate the risk ratio (RR) for each trial (Appendix 1). Using the criteria outlined in this manuscript, these studies are expected to provide the highest level of evidence from the available studies identified in the literature search. A brief account of the studies, including a description of how the cattle were allocated to treatment, the timing of vaccine administration, and a characterization of the vaccines used, can be found in the appendices.
All twenty-two trials reported a cumulative incidence for morbidity. For some trials the case definition for being considered a case was not specified, other studies had clear case definitions for BRD morbidity. Some studies reported crude morbidity and mortality risk (morbidity or mortality due to any cause) while some studies reported BRD-specific morbidity and mortality risk.
M. haemolytica and M. haemolytica + P. multocida vaccines
Studies investigating the effectiveness of several different commercially available vaccines against M. haemolytica (15 trials) and M. haemolytica + P. multocida (3 trials) were summarized, with three out of eighteen trials reporting a statistically significant reduction in BRD morbidity cumulative incidence in vaccinates compared to controls (e.g. upper 95%
confidence interval was less than 1.00) [10, 16, 17] , while four reported an increased risk of BRD morbidity [8, 17, 20] and eleven [9] [10] [11] [12] [13] [14] [15] [18] [19] [20] reported a decreased risk of BRD morbidity cumulative incidence that was not different from control populations (Figure 1 ). The summary RR for these trials is 0.93 with a 95% confidence interval that does not cross 1.0 (0.89-0.98), indicating a statistically significant lower risk of morbidity in vaccinated feedlot cattle compared to controls.
The fifteen trials that investigated the effect of M. haemolytica-only vaccine accounted for 90% of the weighted summary RR; and two out of fifteen trials reported a statistically significant reduction in BRD morbidity cumulative incidence in vaccinates compared to controls Studies utilizing feedlot cattle with pathogen-challenged disease models (Appendix 2)
M. haemolytica vaccines
Three studies reporting five trials were identified that utilized feedlot cattle to evaluate the association between vaccination with commercially available M. haemolytica vaccines and mortality risk and lung lesion severity following induced disease with a transthoracic inoculation of M. haemolytica. [14, 28, 29] All five trials reported increased survival post-challenge and the four trials that reported lung severity, indicated decreased percentage of total lung volume being classified as pneumonic in vaccinates compared to controls.
Studies utilizing dairy or beef calves with naturally occurring disease (Appendix 3)
M. haemolytica and M. haemolytica + P. multocida vaccines
Studies utilizing dairy or beef calves during the first three to six months of life to test the efficacy of a vaccine against M. haemolytica or a combination vaccine against M. haemolytica + P. multocida are not considered to provide a high level of evidence for clinical questions arising from feedlot cattle health problems because of differences in age, housing, and management. One limitation for the conclusions that can be drawn from this group of studies includes the fact that all the feedlot studies with natural disease challenge mixed vaccinated and unvaccinated calves in the same feedlot pens. This mixing may under-estimate the value of vaccination because of the phenomena of herd-immunity. In mixed pens, the vaccinated calves may reduce the disease challenge for unvaccinated controls and unvaccinated calves may increase the disease challenge for vaccinated calves compared to the exposure expected when entire pens are either vaccinated or not vaccinated. Another limitation is that some studies reported crude morbidity and mortality while other studies reported BRD-specific morbidity and mortality. Approximately 59% of the weighted summary RR for morbidity in the feedlot studies was derived from studies using a case definition for BRD as the criteria for being classified as a morbid animal, while 41% of the weighted summary RR came from studies reporting the effect of vaccination in all causes of morbidity. Similarly, approximately 57% of the weighted summary RR for mortality in the feedlot studies came from studies specifying mortalities associated with BRD, while 43% of the weighted summary RR was derived from studies reporting the effect of vaccination on all causes of mortality. If non-BRD mortalities were evenly distributed between vaccinates and controls in these studies, aggregating mortality of all causes to test the association with vaccination status will decrease the risk ratio between vaccinates and non-vaccinated controls.
A thorough search of the published literature and a structured meta-analysis to produce a summary Mantel-Haenszel risk ratio (RR) and 95% confidence interval (95% CI) are helpful tools for making an assessment of the evidence for the effectiveness of vaccination against Mannheimia haemolytica, Pasteurella multocida and Histophilus somni for mitigating the incidence and effect of bovine respiratory disease (BRD) complex in feedlot cattle. However, because of the limitations of the studies used in the meta-analysis and the various specific clinical situations that feedlot veterinarians and producers confront, it is necessary to combine this summary with other sources of information and unpublished data, as well as continued monitoring of recommendations to arrive at the best advice for feedlot clients. 
